Researchers from Canada reviewed the results of 26 trials to determine which of the weight loss jabs are the most effective ...

The Food and Drug Administration approved Eli Lilly’s weight-loss drug Zepbound on Dec. 27 to treat sleep apnea, a common but ...

The federal agency authorized the use of the Eli Lilly & Co. weight loss drug for “treatment of moderate to severe ...

The United States Food and Drug Administration says the shortage of Eli Lilly’s Zepbound and Mounjaro drugs has been resolved ...

The approval supports evidence that GLP-1 drugs improve overall health along with weight loss. In March, the FDA approved Wegovy, from Novo Nordisk, to reduce heart disease risk. Other studies are ...

The FDA also recommends that ... Shelby Knowles/Bloomberg via Getty The weight loss drug Zepbound, generically known as tirzepatide, is also now an approved medication to treat obstructive sleep ...

The first medication for obstructive sleep apnea has been approved by the US Food and Drug Administration (FDA). On Dec. 20 ... “Zepbound promotes weight loss and has been shown to reduce ...

which was approved for weight loss for those with obesity, or who are overweight and have a weight-related health condition, in November 2023. Although the new FDA green light doesn’t expand the ...

Experimental weight-loss drug Retatrutide shows promise, helping obese adults lose up to 22% of their weight in 48 weeks. Mimicking three hormones, it outperforms FDA-approved treatments like Ozempic ...

The FDA approved a new drug treatment for obstructive sleep apnea that improves the condition through weight loss. Sleep expert Dr. Wendy Troxel discusses the impact of the new development.